廣告
香港股市 將在 5 小時 11 分鐘 開市
  • 恒指

    16,828.93
    +317.24 (+1.92%)
     
  • 國指

    5,954.62
    +123.36 (+2.12%)
     
  • 上證綜指

    3,021.98
    -22.62 (-0.74%)
     
  • 道指

    38,503.69
    +263.71 (+0.69%)
     
  • 標普 500

    5,070.55
    +59.95 (+1.20%)
     
  • 納指

    15,696.64
    +245.33 (+1.59%)
     
  • Vix指數

    15.79
    -1.15 (-6.79%)
     
  • 富時100

    8,044.81
    +20.94 (+0.26%)
     
  • 紐約期油

    83.30
    +1.40 (+1.71%)
     
  • 金價

    2,336.10
    -10.30 (-0.44%)
     
  • 美元

    7.8350
    -0.0007 (-0.01%)
     
  • 人民幣

    0.9241
    +0.0003 (+0.03%)
     
  • 日圓

    0.0504
    0.0000 (0.00%)
     
  • 歐元

    8.3837
    +0.0377 (+0.45%)
     
  • Bitcoin

    66,149.41
    -577.17 (-0.86%)
     
  • CMC Crypto 200

    1,430.44
    +15.68 (+1.11%)
     

HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging

  • Ayala Pharmaceuticals Inc (NASDAQ: Ayala) reported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday.

  • At 16 weeks, one of 13 patients treated with AL102 demonstrated an unconfirmed partial response, which HC Wainwright believes signals encouraging initial activity.

  • HC Wainwright reiterated the Buy rating on the stock with a price target of $18.

  • The analyst says that Ayala's initial data is encouraging in the context of the clinical development landscape.

  • Competitor SpringWorks Therapeutics Inc's (NASDAQ: SWTX) nirogacestat hadn't yet shown any responses during the 16-week timeframe.

  • HC Wainwright awaits data on

    • Disease control rate (DCR), as nirogacestat has shown 100% DCR in the Phase 2 trial on desmoid tumors.

    • Longer-term data for AL102 benchmarked to the 29% (5/17) responses observed by approximately 28 months in SpringWorks' Phase 2 trial.

    • Median progression-free survival as SpringWorks Phase 3 trial demonstrated a 71% reduction in the risk of progression vs. placebo.

    • Breakdown in patients treated by each of three dose levels could add context to Ayala's unconfirmed response.

  • Price Action: AYLA shares are up 8.25% at $1.18 during the market session on the last check Wednesday.

Latest Ratings for AYLA

Date

Firm

Action

From

To

Dec 2021

Maxim Group

Initiates Coverage On

Buy

Dec 2021

HC Wainwright & Co.

Initiates Coverage On

Buy

Nov 2021

Jefferies

Upgrades

Hold

Buy

View More Analyst Ratings for AYLA

廣告

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.